Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

Leonie M. Weskamm; Anahita Fathi; MVA-MERS-S Study Group; Matthijs P. Raadsen; Anna Z. Mykytyn; Till Koch; Michael Spohn; Monika Friedrich; Bart L. Haagmans; Stephan Becker; Gerd Sutter; Christine Dahlke; Marylyn M. Addo

doi:10.1016/j.xcrm.2022.100685

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

Leonie M. Weskamm^*
, Anahita Fathi
, MVA-MERS-S Study Group
, Matthijs P. Raadsen
, Anna Z. Mykytyn
, Till Koch
, Michael Spohn
, Monika Friedrich
, Bart L. Haagmans
, Stephan Becker
, Gerd Sutter
, Christine Dahlke
, Marylyn M. Addo

^*Corresponding author for this work

Virology

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

65 Downloads (Pure)

Abstract

The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.

Original language	English
Article number	100685
Journal	Cell Reports Medicine
Volume	3
Issue number	7
DOIs	https://doi.org/10.1016/j.xcrm.2022.100685
Publication status	Published - 19 Jul 2022

Bibliographical note

ACKNOWLEDGMENTS
We thank all volunteers for their participation in this first-in-human phase 1
vaccine trial and their commitment and dedication to research against
emerging CoVs. We would also like to express our sincere gratitude to all trial
center members for their extraordinary work (Clinical Trial Center North GmbH
& Co. KG, Hamburg), especially Saskia Borregaard, Alen Jambrecina, and
Laura Kaltenberg. We also thank Keith Chappell (University of Queensland)
for providing MERS-CoV-S clamp antigen. This work was funded by the
DFG grant AD171/3-1 and the DZIF infrastructure ‘‘Clinical management and
epidemiology of emerging infections’’ [01.702] and FKZ8009801908,
FKZ8009701702, and FKZ80095CLANF.

Publisher Copyright: © 2022 The Author(s)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.xcrm.2022.100685Licence: CC BY-NC-ND

PIIS266637912200221XFinal published version, 3.33 MBLicence: CC BY-NC-ND

Cite this

Weskamm, L. M., Fathi, A., MVA-MERS-S Study Group, Raadsen, M. P., Mykytyn, A. Z., Koch, T., Spohn, M., Friedrich, M., Haagmans, B. L., Becker, S., Sutter, G., Dahlke, C., & Addo, M. M. (2022). Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Reports Medicine, 3(7), Article 100685. https://doi.org/10.1016/j.xcrm.2022.100685

@article{30508b9fcf0f4eb0abdd9078cce5866e,

title = "Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine",

abstract = "The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50\% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.",

author = "Weskamm, \{Leonie M.\} and Anahita Fathi and \{MVA-MERS-S Study Group\} and Raadsen, \{Matthijs P.\} and Mykytyn, \{Anna Z.\} and Till Koch and Michael Spohn and Monika Friedrich and Etienne Bartels and Swantje Gundlach and Thomas Hesterkamp and Verena Kr{\"a}hling and Susan Lassen and Ly, \{My Linh\} and P{\"o}tsch, \{Joseph H.\} and Stefan Schmiedel and Asisa Volz and Zinser, \{Madeleine E.\} and Haagmans, \{Bart L.\} and Stephan Becker and Gerd Sutter and Christine Dahlke and Addo, \{Marylyn M.\}",

note = "ACKNOWLEDGMENTS We thank all volunteers for their participation in this first-in-human phase 1 vaccine trial and their commitment and dedication to research against emerging CoVs. We would also like to express our sincere gratitude to all trial center members for their extraordinary work (Clinical Trial Center North GmbH \& Co. KG, Hamburg), especially Saskia Borregaard, Alen Jambrecina, and Laura Kaltenberg. We also thank Keith Chappell (University of Queensland) for providing MERS-CoV-S clamp antigen. This work was funded by the DFG grant AD171/3-1 and the DZIF infrastructure {\textquoteleft}{\textquoteleft}Clinical management and epidemiology of emerging infections{\textquoteright}{\textquoteright} [01.702] and FKZ8009801908, FKZ8009701702, and FKZ80095CLANF. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = jul,

day = "19",

doi = "10.1016/j.xcrm.2022.100685",

language = "English",

volume = "3",

journal = "Cell Reports Medicine",

publisher = "Cell Press",

number = "7",

}

Weskamm, LM, Fathi, A, MVA-MERS-S Study Group, Raadsen, MP, Mykytyn, AZ, Koch, T, Spohn, M, Friedrich, M, Haagmans, BL, Becker, S, Sutter, G, Dahlke, C & Addo, MM 2022, 'Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine', Cell Reports Medicine, vol. 3, no. 7, 100685. https://doi.org/10.1016/j.xcrm.2022.100685

TY - JOUR

T1 - Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

AU - Weskamm, Leonie M.

AU - Fathi, Anahita

AU - MVA-MERS-S Study Group

AU - Raadsen, Matthijs P.

AU - Mykytyn, Anna Z.

AU - Koch, Till

AU - Spohn, Michael

AU - Friedrich, Monika

AU - Bartels, Etienne

AU - Gundlach, Swantje

AU - Hesterkamp, Thomas

AU - Krähling, Verena

AU - Lassen, Susan

AU - Ly, My Linh

AU - Pötsch, Joseph H.

AU - Schmiedel, Stefan

AU - Volz, Asisa

AU - Zinser, Madeleine E.

AU - Haagmans, Bart L.

AU - Becker, Stephan

AU - Sutter, Gerd

AU - Dahlke, Christine

AU - Addo, Marylyn M.

N1 - ACKNOWLEDGMENTS We thank all volunteers for their participation in this first-in-human phase 1 vaccine trial and their commitment and dedication to research against emerging CoVs. We would also like to express our sincere gratitude to all trial center members for their extraordinary work (Clinical Trial Center North GmbH & Co. KG, Hamburg), especially Saskia Borregaard, Alen Jambrecina, and Laura Kaltenberg. We also thank Keith Chappell (University of Queensland) for providing MERS-CoV-S clamp antigen. This work was funded by the DFG grant AD171/3-1 and the DZIF infrastructure ‘‘Clinical management and epidemiology of emerging infections’’ [01.702] and FKZ8009801908, FKZ8009701702, and FKZ80095CLANF. Publisher Copyright: © 2022 The Author(s)

PY - 2022/7/19

Y1 - 2022/7/19

N2 - The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.

AB - The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies.

UR - https://www.scopus.com/pages/publications/85134778548

U2 - 10.1016/j.xcrm.2022.100685

DO - 10.1016/j.xcrm.2022.100685

M3 - Article

C2 - 35858586

AN - SCOPUS:85134778548

VL - 3

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 7

M1 - 100685

ER -

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this